Nidufexor: Difference between revisions
CSV import |
CSV import Tags: mobile edit mobile web edit |
||
| Line 1: | Line 1: | ||
{{Short description|An overview of the drug Nidufexor}} | |||
{{Drugbox}} | |||
== | ==Overview== | ||
Nidufexor | [[File:Nidufexor_structure.png|thumb|right|Chemical structure of Nidufexor]] | ||
'''Nidufexor''' is a pharmaceutical compound that acts as a selective agonist of the [[farnesoid X receptor]] (FXR). It is being investigated for its potential therapeutic effects in the treatment of [[non-alcoholic steatohepatitis]] (NASH) and other liver-related disorders. FXR is a nuclear receptor that plays a crucial role in the regulation of bile acid homeostasis, lipid metabolism, and glucose metabolism. | |||
== | ==Mechanism of Action== | ||
Nidufexor | Nidufexor functions by activating the farnesoid X receptor, which is predominantly expressed in the liver and intestines. Activation of FXR by Nidufexor leads to a cascade of biological effects, including the suppression of bile acid synthesis, reduction of hepatic triglyceride accumulation, and improvement in insulin sensitivity. These effects make Nidufexor a promising candidate for the treatment of metabolic liver diseases. | ||
== | ==Clinical Development== | ||
Nidufexor is currently undergoing clinical trials to evaluate its efficacy and safety in patients with non-alcoholic steatohepatitis. The drug's ability to modulate FXR activity is being closely studied to determine its potential benefits in reducing liver inflammation and fibrosis, which are key pathological features of NASH. | |||
== | ==Potential Benefits== | ||
The activation of FXR by Nidufexor has several potential therapeutic benefits: | |||
* '''Reduction of Liver Fat:''' By decreasing hepatic triglyceride levels, Nidufexor may help reduce liver fat accumulation, a hallmark of NASH. | |||
* '''Anti-inflammatory Effects:''' FXR activation can lead to decreased expression of pro-inflammatory cytokines, potentially reducing liver inflammation. | |||
* '''Fibrosis Reduction:''' Nidufexor may help in reducing liver fibrosis by modulating pathways involved in fibrogenesis. | |||
[[ | ==Side Effects== | ||
[[Category: | As with any investigational drug, Nidufexor may have side effects. Commonly observed side effects in clinical trials include gastrointestinal disturbances, pruritus, and changes in lipid profiles. Ongoing studies aim to further elucidate the safety profile of Nidufexor. | ||
==Related pages== | |||
* [[Farnesoid X receptor]] | |||
* [[Non-alcoholic steatohepatitis]] | |||
* [[Liver disease]] | |||
* [[Bile acid]] | |||
[[Category:Experimental drugs]] | |||
[[Category:Hepatology]] | [[Category:Hepatology]] | ||
[[Category:Pharmacology]] | |||
Latest revision as of 12:01, 15 February 2025
An overview of the drug Nidufexor
| Nidufexor | |
|---|---|
| [[File:|frameless|220px|alt=|]] | |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Overview[edit]
Nidufexor is a pharmaceutical compound that acts as a selective agonist of the farnesoid X receptor (FXR). It is being investigated for its potential therapeutic effects in the treatment of non-alcoholic steatohepatitis (NASH) and other liver-related disorders. FXR is a nuclear receptor that plays a crucial role in the regulation of bile acid homeostasis, lipid metabolism, and glucose metabolism.
Mechanism of Action[edit]
Nidufexor functions by activating the farnesoid X receptor, which is predominantly expressed in the liver and intestines. Activation of FXR by Nidufexor leads to a cascade of biological effects, including the suppression of bile acid synthesis, reduction of hepatic triglyceride accumulation, and improvement in insulin sensitivity. These effects make Nidufexor a promising candidate for the treatment of metabolic liver diseases.
Clinical Development[edit]
Nidufexor is currently undergoing clinical trials to evaluate its efficacy and safety in patients with non-alcoholic steatohepatitis. The drug's ability to modulate FXR activity is being closely studied to determine its potential benefits in reducing liver inflammation and fibrosis, which are key pathological features of NASH.
Potential Benefits[edit]
The activation of FXR by Nidufexor has several potential therapeutic benefits:
- Reduction of Liver Fat: By decreasing hepatic triglyceride levels, Nidufexor may help reduce liver fat accumulation, a hallmark of NASH.
- Anti-inflammatory Effects: FXR activation can lead to decreased expression of pro-inflammatory cytokines, potentially reducing liver inflammation.
- Fibrosis Reduction: Nidufexor may help in reducing liver fibrosis by modulating pathways involved in fibrogenesis.
Side Effects[edit]
As with any investigational drug, Nidufexor may have side effects. Commonly observed side effects in clinical trials include gastrointestinal disturbances, pruritus, and changes in lipid profiles. Ongoing studies aim to further elucidate the safety profile of Nidufexor.
